Analyst Price Targets — KPTI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 6, 2026 10:13 am | — | H.C. Wainwright | $13.00 | $9.41 | TheFly | Karyopharm price target raised to $13 from $8 at H.C. Wainwright |
| April 27, 2026 10:46 am | — | Piper Sandler | $16.00 | $8.66 | TheFly | Karyopharm price target raised to $16 from $8 at Piper Sandler |
| March 9, 2026 8:20 pm | — | UBS | $28.00 | $8.49 | TheFly | Karyopharm initiated with a Buy at Rodman & Renshaw |
| December 17, 2025 12:01 pm | — | Piper Sandler | $12.00 | $6.33 | StreetInsider | Piper Sandler Highlights Karyopharm Therapeutics (KPTI) As a 2026 Top Pick |
| December 17, 2025 12:01 pm | — | Goldman Sachs | $12.00 | $6.33 | StreetInsider | Piper Sandler Highlights Karyopharm Therapeutics (KPTI) As a 2026 Top Pick |
| November 4, 2025 2:49 pm | Brian Abrahams | RBC Capital | $19.00 | $5.60 | TheFly | Karyopharm price target lowered to $19 from $30 at RBC Capital |
| October 13, 2025 10:10 am | Robert Burns | H.C. Wainwright | $15.00 | $5.50 | TheFly | Karyopharm upgraded to Buy from Neutral at H.C. Wainwright |
| October 9, 2025 11:13 am | — | Robert W. Baird | $21.00 | $5.90 | TheFly | Karyopharm price target lowered to $21 from $25 at Baird |
| October 8, 2025 6:56 pm | — | Leerink Partners | $6.00 | $5.91 | TheFly | Karyopharm price target lowered to $6 from $8 at Leerink |
| June 10, 2024 5:39 am | Brian Abrahams | RBC Capital | $3.00 | $0.95 | StreetInsider | RBC Capital Reiterates Outperform Rating on Karyopharm Therapeutics (KPTI) |
Latest News for KPTI
NEWTON, Mass., July 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,649 restricted stock units (RSUs) to four newly-hired employees.
NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will participate in a virtual fireside chat hosted by Cantor on June 8, 2026 at 12:00 p.m.
Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis Transcript
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
– New Data will Highlight a Post-Hoc Analysis from Phase 1 Portion of SENTRY Trial that Indicates Achievement of SVR35 with Selinexor plus Ruxolitinib May Predict Overall Survival – – Selected by EHA's Scientific Program Committee as One of the Top Abstracts to be Presented – NEWTON, Mass., June 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KPTI.
U.S. House Trading
No House trades found for KPTI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.